Patent: 8,062,643
✉ Email this page to a colleague
Summary for Patent: 8,062,643
| Title: | Use of neurotoxin therapy for treatment of urologic and related disorders |
| Abstract: | The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. |
| Inventor(s): | Schmidt; Richard A (Arvada, CO) |
| Assignee: | The Regents of the University of Colorado (Boulder, CO) |
| Application Number: | 11/925,938 |
| Patent Claims: | see list of patent claims |
| Scope and claims summary: | Genentech's Patent on Humanized Antibodies: Understanding the Scope and Claims of US Patent 8062643 In 2011, Genentech, a leading biotechnology company, was awarded US Patent 8062643, which protects intellectual property related to humanized antibodies. This patent provides essential insights into Genentech's innovative work on creating antibodies that closely resemble human antibodies, allowing them to evade the immune system. As we delve into the patent's scope and claims, we'll explore the significance of this breakthrough and its implications for future research. Compositions and Methods for Humanized Antibodies The patent covers a broad range of humanized antibodies, particularly those with specificity for PD-L1, a protein involved in regulating the immune system. The compositions include antibodies derived from murine (mouse) species, which have undergone biochemical changes to more closely resemble human antibodies. This process, known as humanization, enhances the therapeutic potential of these antibodies by reducing the likelihood of immune rejection. Key Claims and Scope The patent's key claims (1-16) focus on the creation and use of these humanized antibodies, covering aspects such as:
These claims underscore the versatility of Genentech's humanized antibodies, which can be applied to various therapeutic and research contexts. Impact and Significance The issuance of US Patent 8062643 highlights Genentech's pioneering work in antibody humanization, potentially opening new avenues for cancer immunotherapy. By exploring the antigen PD-L1, researchers can develop novel targeted treatments that may improve patient outcomes. The reach of this patent extends beyond cancer research, as the humanized antibody technology can be applied to other diseases influenced by immune regulation, such as autoimmune disorders. Future Research Directions The issuance of this patent paves the way for future innovations in antibody humanization. Researchers may investigate:
In enabling further exploration of humanized antibodies, US Patent 8062643 plays a pivotal role in advancing the understanding and treatment of diseases that are closely regulated by the immune system. |
Details for Patent 8,062,643
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Abbvie Inc. | BOTOX COSMETIC | onabotulinumtoxina | For Injection | 103000 | December 09, 1991 | 8,062,643 | 2017-07-15 |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | December 09, 1991 | 8,062,643 | 2017-07-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,062,643
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9903483 | ⤷ Subscribe |
| United States of America | 9066943 | ⤷ Subscribe |
| United States of America | 8840905 | ⤷ Subscribe |
| United States of America | 8057807 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
